Study details
Enrolling now
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Arkansas Children's Hospital Research Institute
NCT IDNCT07148739ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
95
Study length
about 5.6 years
Ages
3+
Locations
2 sites in AR, WA
About this study
This trial is testing a treatment for Cystic Fibrosis (CF) that includes new drugs and genetic testing. The goal is to find out how these drugs work, who will respond well, and avoid unnecessary side effects or expensive treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Elexacaftor / Ivacaftor / Tezacaftor
- 2.Use therapeutic drug monitoring
PhasePhase 4
DrugElexacaftor
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Respiratory System Agent (Cytochrome P450 1A2 Inhibitors), ivacaftor
Drug routes
oral (Oral Tablet)
Body systems
Respiratory